Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

1. Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
   Article
2. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametricEuropean journal of nuclear medicine and molecular imaging · 2020
   Article
3. Integration of dynamic parameters in the analysis ofEuropean journal of nuclear medicine and molecular imaging · 2020
   Article
4. A Nomogram ModelingFrontiers in oncology · 2020
   Article
5. Correlation of multimodalTheranostics · 2020
   Article
6. Re-evaluation of the diagnostic performance ofEuropean journal of nuclear medicine and molecular imaging · 2019
   Article
7. A highThe British journal of radiology · 2018
   Article
8. Static and dynamicEuropean journal of nuclear medicine and molecular imaging · 2018
   Article
9. Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas.PloS one · 2018
   Article
10. A kinetic solution for the paradoxical difference between F-Dopa and methionine.European journal of nuclear medicine and molecular imaging · 2017
    Article
11. "The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?European journal of nuclear medicine and molecular imaging · 2017
    Article
12. The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: AMolecular imaging
    Article

Corrections and comments

• Commented on by
  "The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?2017
• Commented on by
  A kinetic solution for the paradoxical difference between F-Dopa and methionine.2017
• Comment on
  Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.2017

Authors and funding

3 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as